Cargando…
In vivo, ex vivo and in vitro dasatinib activity in chronic lymphocytic leukemia
Dasatinib inhibits the breakpoint cluster region-Abelson murine leukemia 1 (BCR-ABL1) gene along with other kinases known to be overexpressed and abnormally active in patients with chronic lymphocytic leukemia (CLL). The current study used primary leukemic cells obtained from 53 patients with CLL th...
Autores principales: | Giannopoulos, Krzysztof, Karczmarczyk, Agnieszka, Karp, Marta, Bojarska-Junak, Agnieszka, Kosior, Kamila, Kowal, Małgorzata, Tomczak, Waldemar, Hus, Marek, Machnicki, Marcin, Stokłosa, Tomasz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905539/ https://www.ncbi.nlm.nih.gov/pubmed/33732361 http://dx.doi.org/10.3892/ol.2021.12546 |
Ejemplares similares
-
Gene Expression Profiling Predicts Sensitivity of Chronic Lymphocytic Leukemia Cells to Dasatinib
por: Blätte, Tamara J., et al.
Publicado: (2020) -
Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia
por: Grzywnowicz, Maciej, et al.
Publicado: (2012) -
TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia
por: Szymańska, Agata, et al.
Publicado: (2018) -
Intracellular IL-4 and IFN-γ expression in iNKT cells from patients with chronic lymphocytic leukemia
por: Bojarska-Junak, Agnieszka, et al.
Publicado: (2018) -
Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity
por: Hus, Iwona, et al.
Publicado: (2013)